Abbott Park, Ill., Jan. 22, 2017 — A series of data presentations this week continued to expand the growing body of clinical evidence supporting the use of Abbott’s proprietary BurstDR™ stimulation for the treatment of chronic pain. The latest research was present ed during the 2017 North American Neuromodulation Society (NANS) annual meeting, and focused on the benefits of BurstDR stimulation for patients with a variety of chronic pain conditions.
Data were collected at centers across Europe, where BurstDR stimulation has been approved since 2014. Researchers highlighted potential benefits of BurstDR stimulation over 10 kHz high-frequency stimulation for patients with Failed Back Surgery Syndrome (FBSS), as well as significant improvements for patients with chronic upper and lower limb pain. The data also emphasized the ability of this therapy to improve quality of life and reduce catastrophizing (irrational thinking) among chronic pain patients.
"For years, data from single-center, multi-center and randomized controlled clinical trials have confirmed the benefits of BurstDR stimulation for patients suffering from chronic pain," said Allen Burton, M.D., medical director of neuromodulation at Abbott. "Throughout NANS 2017, the data presented on BurstDR stimulation consistently demonstrated that the therapy is a good option for new groups of patients currently underserved by existing therapy options. It was exciting to receive direct clinical feedback on the impact of this transformational therapy."
BurstDR Stimulation Shows Benefits over 10 kHz High-Frequency Stimulation for FBSS Patients
Researchers at the Rheinische Friedrich Wilhelms University Hospital in Bonn, Germany, reported on an extended long-term follow-up of a previously published comparative study assessing the safety and efficacy of both BurstDR stimulation and 10 kHz high-frequency stimulation in patients with failed back surgery syndrome (FBSS) with predominant back pain. FBSS is characterized by continued back or leg pain despite undergoing lower spinal surgery.
While both technologies have demonstrated an improvement in failed back surgery syndrome with predominant back pain over traditional tonic SCS, this trial is the first randomized, controlled study directly comparing BurstDR stimulation and 10 kHz high-frequency tonic stimulation.
In the study, led by Thomas Kinfe, M.D., Ph.D., professor of neurosurgery at the Rheinische Friedrich Wilhelms University Hospital in Bonn, Germany, a total of 16 patients were followed for up to 20 months. Patients were evaluated for intensity of back and leg pain as measured by the Visual Analog Scale (VAS). The study found:
Additional Benefits of BurstDR Stimulation
Throughout NANS 2017, researchers from Germany, the U.K., and Belgium showcased the ability of BurstDR stimulation to positively impact patients suffering different types of chronic pain. Researchers also examined the ability of the therapy to improve quality of life. In addition, researchers assessed the ability of BurstDR stimulation to favorably impact on psychological characteristics frequently seen in combination with chronic pain. These psychological traits frequently seen in combination with pain include catastrophizing, anxiety, and depression.
These real-world results expand on the outcomes reported in the SUNBURST IDE Study, which led to a superiority labeling from the FDA in October 2016 for BurstDR stimulation vs traditional tonic stimulation.
About Abbott's Chronic Pain Portfolio
Chronic pain affects approximately 1.5 billion people worldwide, more than heart disease, cancer and diabetes combined. The condition can negatively impact personal relationships, work productivity and a patient’s daily routine. Abbott is a global leader in the development of chronic pain therapy solutions and the only medical device manufacturer in the world to offer radiofrequency ablation (RFA) and spinal cord stimulation (SCS) therapy solutions including BurstDR stimulation and stimulation of the dorsal root ganglion (DRG) for the treatment of chronic pain.
At Abbott, we're committed to helping people live their best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world -- in nutrition, diagnostics, medical devices and branded generic pharmaceuticals -- that create more possibilities for more people at all stages of life. Today, 74,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.
For further information: Abbott Media: Justin Paquette, 651-756-6293 or Abbott Financial: J.C. Weigelt, 651-756-4347
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.